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Abstract: Background: This study describes the prevalence of non-steroidal anti-inflammatory
drug (NSAID) use, and analyses prescribing patterns of NSAIDs and associated gastroprotection.
Methods: The study population consisted of 5650 workers at the General Motors automobile assembly
plant in Zaragoza, Spain. NSAID prescription data for 2014 were obtained from the prescription
database of Aragon (Spain). NSAID consumption was determined based on the number of defined
daily doses purchased per year. Heavy NSAIDs users were identified using Lorenz curves. Results:
NSAID use in the cohort was high (40.7% of workers, 95% CI 39.4–41.9). The prescription of proton
pump inhibitors increased with age. Gastrointestinal protection was lacking in some participants who
were being treated with drugs associated with a high risk of gastrointestinal bleeding. Heavy NSAID
users (defined as those above the 95th percentile of consumption), accounted for 26% of total DDDs,
and consumed a greater proportion of coxibs than non-heavy users. Conclusions: The rate of NSAID
consumption in the cohort was high. To reduce the risk of gastrointestinal complications, monitoring
and adequate gastroprotection are essential in patients who are prescribed NSAIDs for long periods
of time or who are treated concomitantly with drugs that increase the risk of gastrointestinal bleeding.
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1. Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed
medications for inflammatory and musculoskeletal conditions [1,2]. Their mechanism of action
consists of the inhibition of cyclooxygenase (COX) enzymes. This in turn impairs the synthesis and
downstream effects of prostaglandins, prostacyclins, and thromboxanes. NSAIDs include traditional
NSAIDs (e.g., ibuprofen, diclofenac, naproxen) and selective COX-2 inhibitors (coxibs). While NSAID
treatment is associated with an increased risk of serious upper gastrointestinal (GI) events, this risk
can be mitigated by prescribing a coxib rather than a non-selective NSAID [3,4].
The EPISER study [5] reported a rate of NSAID-related GI complications of 23.7%.
Several epidemiological studies have attempted to estimate the risk of cardiovascular and GI events
associated with NSAID use in general and with the use of individual NSAIDs [6,7]. The increased risk of
gastrointestinal damage is common to all NSAIDs studied, is dose dependent, and is associated with
long-term use [8]. Specifically, digestive adverse events should be monitored.
Gastropathy is one of the most important health problems caused by NSAIDs. Its clinical
expression varies considerably, ranging from dyspepsia to serious complications that require
hospitalisation (e.g., upper GI bleeding) [8,9]. The risk of NSAID-associated gastropathy
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can be increased by a variety of patient-related (e.g., age, history of peptic ulcer, smoking,
alcohol consumption) and treatment-related (dose, duration, and type of NSAID used) factors,
and by the concomitant use of other drugs including systemic corticosteroids, oral anticoagulants,
platelet aggregation inhibitors, and other NSAIDs [10,11]. Where possible, physicians may prescribe
lower doses of NSAIDs for short durations to reduce the risk of serious upper GI events, particularly in
the subgroup of patients with the greatest background risk [8,10].
NSAID use is high [1], and is associated with the concomitant consumption of proton pump
inhibitors (PPIs), which are frequently used to prevent NSAID-induced GI damage [12]. In this
analysis of NSAID consumption in a cohort of workers, we analysed patterns of NSAID prescription
and characterized the profile of heavy NSAID users and the consumption of PPIs by individuals
prescribed NSAIDs.
2. Materials and Methods
The Aragon Workers’ Health Study (AWHS) is a prospective longitudinal study, with the aim
of characterizing cardiometabolic factors in a population of middle-aged Mediterranean workers.
We analysed data from routine annual health examinations of workers at a Spanish automobile
assembly plant in Figueruelas, Zaragoza (Spain), who voluntarily agreed to participate in the study.
The participants (n = 5650) were recruited between February 2009 and May 2010. Most of the workers
in the cohort (86.5% of men and 60.5% of women) performed manual tasks. Active follow-up of
participants is expected to continue through 2020. Further information on the AWHS can be found in
Casasnovas et al. [13].
This observational descriptive study was designed to assess the prevalence of NSAID use in
the AWHS cohort, and to characterise heavy NSAID users and the prescribing patterns of NSAIDs
and associated gastroprotective agents in 2014. NSAID prescription data for AWHS participants
was gathered from FarmaSalud, the prescription database of the government of Aragon, the Spanish
autonomous community in which the assembly plant is located. This database collects data on all
prescriptions dispensed at pharmacies in Aragon via the public health care system (i.e., prescribed
by either a company physician or by general practitioners working in the public health system).
FarmaSalud does not record prescriptions issued by private physicians or hospitals. Each record in
the database corresponds to a prescription and contains the following information: an anonymous
patient code, patient sex and birth date, dispensing date, Anatomical Therapeutic Chemical (ATC)
code of the prescribed drug, number of defined daily doses (DDD), and number of packages dispensed.
Drugs are classified according to the 2016 version of the World Health Organization ATC/DDD
system [14]. Using an encrypted code provided by AWHS researchers, we identified prescriptions
corresponding to NSAIDs (ATC code M01A).
Rates of dispensation per 100 workers and corresponding 95% confidence intervals (95% CI) were
calculated. Rates were calculated as the number of individuals per 100 workers who filled at least one
prescription for an NSAID in 2014. Data were further analysed after stratification for age and sex.
To assess the use of gastroprotective agents in conjunction with NSAIDs, we assessed the
concomitant use of NSAIDs and proton pump inhibitors (PPI), which is the class of drug most
commonly used to prevent NSAID-induced gastropathy in Spain [12]. Patients were categorised as
users of gastroprotective agents if they filled a prescription for a PPI (ATC code A02BC) within two
months of filling the first NSAID prescription (set as index date). Among workers treated with NSAIDs,
the concomitant use of other drugs that increase the risk of GI damage was also analysed. The drugs
included in this analysis were platelet aggregation inhibitors (B01AC), anticoagulants (B01AA, B01AB,
B01AE, B01AF), corticosteroids (H02, with the exception of topically or locally applied corticosteroids),
and selective serotonin-reuptake inhibitors (SSRIs, ATC code N06AB). Concomitantly prescribed drugs
were defined as those prescribed within two months of the NSAID prescription. A χ2 test was used to
compare the use of gastroprotective agents. Statistical significance was set at p < 0.05.
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The annual amount of DDDs was used to categorise the NSAID consumption. We set the limit for
low use to 30 DDDs and chronic use to more than 90 DDDs. Lorenz curves were used to identify heavy
consumers of NSAIDs within the cohort. This analytical tool was applied to NSAID use to highlight
the unequal distribution of drug consumption within the study population [15,16]. In the Lorenz
curve, the x-axis represents the accumulated percentage of drug users and the y-axis the accumulated
percentage of total consumption (DDD) per year. Thus, it shows the proportion of drug use accounted
for by percentiles of drugs users, ranked according to their volume of consumption, measured in DDD.
We defined heavy users of NSAIDs as those above the 95th percentile of consumption (i.e., the 5% of
patients with the highest DDD values). Within this group, distribution by age and prescribing patterns per
pharmacological subgroup were compared with those observed for the remainder of NSAID consumers
(non-heavy users). The two groups were compared using a χ2 test, with statistical significance set at
p < 0.05.
3. Ethics
Participants in the AWHS provided written informed consent on enrolment. The present study
was approved by the Clinical Research Ethics Committee of Aragon (RAB-EST-2014-01. FIS13/1668.
Approved February 2014).
4. Results
Of the 5650 participants in the AWHS, 2294 (40.7%) filled at least one prescription for an NSAID in
2014. Analysis of the rate of prescription of NSAIDs by age group and sex (Table 1) revealed a higher
rate in older age groups. In men, the rate for those under 50 years of age was the lowest rate: 32.9%
(95% CI 30.3–35.5), while the highest rate was observed for those over 59 years of age (46.7%, 95% CI
43.7–49.7). For women, the total rate of dispensation of NSAIDs was 38.4%. NSAID consumption in
this group also increased with age, with higher rates observed in the oldest age group (over 55 years).
Table 1. Rate of dispensation of non-steroidal anti-inflammatories stratificated for age and sex in
the cohort of workers in 2014.
Age Groups (Years)
<50 (95% CI) 50–54 (95% CI) 55–59 (95% CI) >59 (95% CI) Total (95% CI)
Male 32.9 (30.3–35.5) 41.9 (39.0–44.8) 43.0 (40.7–45.3) 46.7 (43.7–49.7) 40.8 (39.5–42.2)
Female 32.1 (25.7–38.4) 40.8 (29.4–52.3) 48.5 (36.6–60.4) 53.3 (35.5–71.2) 38.4 (33.5–43.3)
TOTAL 32.8 (30.4–35.2) 41.8 (39.0–44.7) 43.2 (40.9–45.4) 46.9 (43.9–49.8) 40.7 (39.4–42.0)
Number of workers in the cohort: 5650 (Male: 5268; Female: 382). 95% CI: 95% confidence intervals. Rate per
100 workers.
The most commonly prescribed NSAID subgroup was non-selective NSAIDs: prescriptions for
drugs corresponding to the ATC codes M01AE (propionic acid derivatives) and M01AB (acetic acid
derivatives) were filled by 69.9% and 28.9% of workers, respectively. The next most prescribed subgroups
were M01AX that includes symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) and M01AH
(selective cyclooxygenase-2 inhibitors or coxibs). Ibuprofen was the most frequently prescribed NSAID
(48.2% of workers treated with NSAIDs were prescribed this drug). The next most commonly prescribed
traditional NSAIDs were diclofenac and dexketoprofen. Etoricoxib was prescribed more frequently than
celecoxib, while chondroitin sulfate was the most prescribed drug of the M01AX subgroup.
Of the participants who were prescribed NSAIDs and PPIs, 71.7% were over 55 years of age.
In the group of workers that used NSAIDs without gastroprotection, 311 (22.5%) were over 59 years of
age. The prescription of gastroprotective agents was significantly higher in patients who were being
treated with NSAIDs and platelet aggregation inhibitors, anticoagulants, or corticosteroids, although not
all workers using these drugs associated with a high risk of GI events had been prescribed a PPI (Table 2).
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Table 2. Characteristics of individuals treated with non-steroidal anti-inflammatories (NSAID) or
NSAID and proton pump inhibitors and concomitant drugs at a high risk of gastrointestinal events.
People Treated with NSAID
without PPI
People Treated with
NSAID and PPI p-Value
Number of individuals 1381 690
Gender, n (%)
Male 1278 (92.5) 665 (96.4)
Female 103 (7.5) 25 (3.6)
Age groups, n (%)
<50 years 320 (23.2) 82 (11.9) <0.001
50–54 years 268 (19.4) 113 (16.4)
55–59 years 482 (34.9) 273 (39.5)
>59 years 311 (22.5) 222 (32.2)
Concomitant medical therapy, n (%)
Anticoagulant drugs 15 (1.1) 25 (3.6) <0.001
Platelet aggregation
inhibitors 47 (3.4) 78 (11.3) <0.001
Corticosteroids 17 (1.2) 23 (3.3) 0.001
SSRI 33 (2.4) 24 (3.5) 0.150
NSAID: Non-steroidal anti-inflammatory drugs. PPI: Proton Pump Inhibitors. SSRI: Selective
Serotonin-Reuptake Inhibitor. Anticoagulants (Vitamin K antagonists 13 patients; Heparins: 24 patients;
Direct factor Xa inhibitors: three patients). People treated with an NSAID and PPI filled a prescription
for a PPI within two months of filling the first NSAID prescription (Attached to Table 2).
The total consumption of NSAIDs in the cohort was 76 DDD/1000 inhabitants per day (DID)
in 2014. In total, 1130 workers were prescribed <31 DDD of NSAIDs, while 484 (21.1%) were
prescribed >90 DDD. The Lorenz curve (Figure 1) deviated to the extreme upper left, indicating
that a small number of workers (heavy users) accounted for a substantial portion of the total number
of DDDs. Heavy NSAID users in our study, defined as those above the 95th percentile of consumption,
were responsible for 26.6% of the total number of DDDs in the cohort. The mean consumption of
NSAIDs within this group was 362 DDD/year.
Rates of prescription of coxibs (14.2% vs. 6.8%, p < 0.001) and SYSADOAs (37.8% vs. 16.3%, p < 0.001)
among heavy NSAID users were significantly higher than those observed for non-heavy users (Table 3).









Age group, n (%)
<50 years 6 (5.2) 478 (22.0) <0.001
50–54 years 23 (20.0) 468 (21.5)
55–59 years 40 (34.8) 767 (35.3)
>59 years 46 (40.0) 462 (21.2)
NSAID subgroup, n (% of total prescriptions)
M01AB Acetic acid derivatives and related substances 249 (15.1) 1102 (18.7) <0.001
M01AE Propionic acid derivatives 511 (30.9) 3342 (56.7) <0.001
M01AH Selective COX-2 inhibitors (coxibs) 234 (14.2) 396 (6.7) <0.001
M01AX Other anti-inflammatory and antirheumatic agents 624 (37.8) 968 (16.4) <0.001
Others (oxicams and fenamates) 33 (2.0) 82 (1.4) <0.001
Total prescriptions 1651 5890
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Figure 1. Lorenz curve of non steroidal anti-inflammatory drugs use in the cohort of workers, 2014.
5. Discussion
NSAIDs were widely used in our cohort: 40.7% of workers received an NSAID prescription
in 2014. This rate is considerably higher than the rates reported in other studies of the general
population; a Finnish study conducted in 2000 reported a prevalence of 17.1% [17], while a 2005 study
in Denmark reported a rate of 16.9% [18]. In Spain, a study carried out in Navarra found that 14% of
the general population had been treated with an NSAID during the first three months of 2016 [19].
It should be borne in mind that our cohort mainly consisted of younger individuals, most of whom
were men. A high rate of NSAID use would not be exp cted in this group; the s bgroups with
the highest ates of NSAID use are the elderly, women, and tients with r umatic diseases [17,18].
However, studies have shown a strong c rrelation between the prevalence of musculoskeletal disorders
and NSAID use [17,19]. As such, the fact that all participants in the present study were automotive
industry workers, in whom the prevalence of musculoskeletal disorders that require NSAID treatment
may be increased [20], may explain the higher than expected rate of NSAID prescription observed.
Using the DDD per 1000 inhabitants per day (DID) as the unit of measure, NSAID consumption
in the cohort was 76 DID, which is significantly higher than that reported in Spain in 2012 (49 DID) [2]
or in Navarra in 2016 (<40 DID) [19]. However, the results of the analyses of the most commonly
prescribed NSAIDs (ibuprofen and related compound [M01AE]) were i gr em nt with those
reported n previous studies [1,17–19].
Several studies have shown that the use of NSAIDs is associated with many adverse effects and
hospitalizations due to GI complications [6,21]. According to a study by Laporte and coworkers [22],
38% of all cases of GI haemorrhage were attributable to the use of NSAIDs (152 cases per million
inhabitants/year). Factors that increase NSAID-associated toxicity include age, a previous history of
peptic ulcers, and the concomitant use of other drugs, including other NSAIDs, oral anticoagulants,
platelet aggregation inhibitors (including low-dose aspirin), and corticosteroids [10].
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In our cohort, 311 patients over 59 years of age were prescribed an NSAID without a gastroprotective
agent. A recent study that analysed hospital admissions for NSAID-induced gastropathy found that
the most common risk factors for these admissions were age and concomitant treatments with other
drugs that enhance the GI toxicity of NSAIDs. The same study found that a large proportion of patients
who met the criteria for gastroprotection were not prescribed gastroprotective drugs [21].
In agreement with previous findings [2,19,23], the most commonly used NSAIDs in the cohort were
ibuprofen and diclofenac, which are associated with a low-to-intermediate risk of GI complications,
depending on the doses used [24–26]. COX-2 inhibitors and SYSADOAs also have a lower GI risk
profile. Our analyses revealed the possible underutilization of gastroprotective agents in individuals
of over 60 years of age and in patients treated concomitantly with drugs that increase the risk
of bleeding (e.g., platelet aggregation inhibitors and anticoagulants). Although other studies have
reported inadequate gastroprotective treatment in patients treated with NSAIDs, either due to over-
or underutilization [21,23,27,28], patients treated with NSAIDs and concomitant platelet aggregation
inhibitors usually receive gastroprotection [23]. However, the rate of use of gastroprotective agents is
lower in patients treated with low-dose acetylsalicylic acid [2], for which there appears to be a lower
perception of risk on the part of medical professionals. There is considerable variability in the literature
regarding the use of gastroprotective agents in patients receiving concomitant NSAIDs and an SSRI agent:
some studies have reported no increased risk of bleeding [6,29], which may explain no differences in
the use of gastroprotective agents in these patients in the cohort.
Methods used to detect high levels of drug consumption usually focus on patients who consume
the highest number of DDDs per year [16,17,27]. In our cohort, NSAID use increased with age.
Moreover, almost 75% of heavy users were 55 or older. Other studies have reported a high prevalence
of heavy NSAID use among elderly patients [17,27]. We found that among patients treated with
NSAIDs, the prescription profile of heavy users differed to that of other users: a larger proportion
of the former group were prescribed SYSADOAs and coxibs, while traditional NSAIDs were more
commonly prescribed in the latter group.
In our cohort, chondroitin sulfate was the most commonly prescribed SYSADOA, particularly
among heavy users of NSAIDs, despite a lack of solid evidence supporting its efficacy [30]. The latest
revision of the NICE guide does not recommend the use of chondroitin sulfate in osteoarthritis
patients [31], despite its good safety profile.
High doses and/or long treatment durations may account for the high levels of NSAID
consumption observed in the heavy user subgroup. Both these scenarios are associated with
an increased risk of GI toxicity [6,8,24,27]. We found that heavy users were prescribed an average of
362 DDDs of an NSAID per year, implying a consumption of one standard dose per day for the entire
year by participants in this group. Almost 75% of heavy users were older than 55 years. Both age and
heavy use of NSAIDs are risk factors of gastrointestinal damage. In these situations, GPs are prone to
select coxib or SYSADOA because these drugs have a low risk of gastrointestinal toxicity [6].
The main limitation of this study relates to the source of data used. In analysing the number
of NSAID prescriptions dispensed at pharmacies in Aragon, we may have underestimated NSAID
consumption in this population, since these drugs can be obtained without prescription. As such,
the true rate of NSAID use may be higher than that reported here. Furthermore, because the
prescription data available in the FarmaSalud database does not include clinical variables, it was
not possible to determine the appropriateness of the treatments prescribed. This is an important factor
to consider when assessing the relevance of gastroprotection in this group. Another limitation relates
to the study population: since this cohort worked exclusively in the automotive sector, and the study
population is largely composed of men, reflecting the sex distribution in the factory, the results obtained
could present some differences with the general population.
Baseline data from the AWHS cohort show a high prevalence of cardiovascular risk factors [13].
Follow-up of this cohort will allow the assessment of cardiovascular events and study the relation with
the drugs consumed, as NSAIDs.
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6. Conclusions
Based on our findings, we can conclude that the use of NSAIDs in this cohort of workers is
much higher than that found in the general population, probably due to the greater prevalence of
musculoskeletal pathologies associated with the specific work activities of the cohort. The cohort
included a group of patients who were prescribed NSAIDs for very long periods of time, which may
increase the risk of adverse effects associated with these drugs. Exposure of patients to long term
use of NSAIDs should be reduced by regular analysis of a patient’s pain and a consideration of other
treatment options.
Physicians should carefully weigh the risks and benefits of prescribing NSAIDs in patients at a high
risk of gastrointestinal damage: gastroprotection with PPI is necessary when dealing with older people
or people treated with drugs that increases serious gastrointestinal events.
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